Incidence and Risk Factors for Invasive Fungal Infections in Patients Initiating Tumor Necrosis Factor-Alpha...

Area of Science:

• Immunology
• Infectious Diseases
• Rheumatology

Background:

• Tumor necrosis factor-alpha (TNF-a) inhibitors are widely used for inflammatory conditions.
• Understanding the risk of invasive fungal infections (IFIs) is crucial for patient safety.
• Previous data on IFI incidence with TNF-a inhibitors in real-world settings is limited.

Purpose of the Study:

• To determine the incidence of IFIs in patients with inflammatory bowel disease (IBD) or rheumatoid arthritis (RA) initiating TNF-a therapy.
• To identify the types of IFIs and associated risk factors.

Main Methods:

• Retrospective analysis of a commercial claims database.
• Inclusion of patients with IBD or RA who started TNF-a therapy between [date] and [date].
• Identification of IFI cases based on diagnostic codes and assessment of incidence within 1 year of therapy initiation.

Main Results:

• Less than 0.5% of patients developed an IFI within 1 year of initiating TNF-a therapy.
• Histoplasmosis was the most common type of IFI.
• IFI incidence varied by geographic region, patient comorbidities, and concomitant use of other immunosuppressive medications.

Conclusions:

• The risk of IFI is low in patients with IBD or RA treated with TNF-a inhibitors.
• Awareness of regional variations and patient-specific factors is important for risk assessment.
• Further research may be warranted to refine risk stratification strategies.